Choosing Healthcare ETFs: Why IHE Outperforms IBB for Many Investors

The iShares U.S. Pharmaceuticals ETF (IHE) offers lower costs, higher dividend yield (1.4% vs 0.2%), and better 5-year returns (79% vs 38%) compared to the iShares Biotechnology ETF (IBB). IHE focuses on 53 established drugmakers with lower volatility, while IBB provides broader exposure to 243 biotech firms with higher risk. IHE may be preferable for income-focused investors, though IBB suits those seeking broader biotech sector exposure.

11/07/2026, 11:15 AM • The Motley Fool

Mexico Animal Healthcare Market Size and Share Analysis - Industry Trends and Growth Forecasts (2026-2031) | Diagnostics and Pet Care Fuel Growth to USD 3.34 Billion

Mexico's animal healthcare market is projected to grow from USD 2.13 billion in 2025 to USD 3.34 billion by 2031, with a CAGR of 7.84%. Growth is driven by rising companion animal spending, expanding livestock production, stronger biosecurity requirements, and innovation in veterinary diagnostics. Key challenges include high costs, limited rural infrastructure, and counterfeit medicines.

11/06/2026, 10:00 AM • GlobeNewswire

Zoetis: 3 Key Takeaways for Long-Term Investors

Zoetis reported a 1% organic revenue decline in Q3 2026, pressured by lower veterinary clinic visits and generic competition in pet care. However, global livestock revenue grew 7% to $797 million, offsetting weakness. The company is deploying promotional strategies to defend market share in dermatology and relying on lifecycle innovations like Simparica Duo to extend core product franchises. Management expects continued macro headwinds into 2027 but maintains a long-term growth thesis centered on innovation and new therapeutic categories.

11/05/2026, 9:47 PM • The Motley Fool

3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now

Rising interest rates have pushed dividend stocks lower, creating buying opportunities. AT&T, Pfizer, and Zoetis are trading at low valuations with attractive dividend yields of 5.3%, 5.8%, and 2.6% respectively, despite market concerns about competition, restructuring, and slowing growth.

10/27/2026, 2:49 PM • The Motley Fool

Europe Companion Animal Diagnostics Market Size and Forecast, 2021 - 2031 | AI-Enabled Testing and Preventive Pet Care Fuel 9.5% CAGR and a US$2.27 Billion Opportunity

Europe's companion animal diagnostics market is projected to reach US$2.27 billion by 2031, growing at a 9.5% CAGR from 2024-2031. Growth is driven by AI-enabled testing, preventive pet care adoption, technological advancements, and rising pet insurance uptake. Germany and the UK lead the market, with veterinary hospitals and clinics as the largest end-user segment. Key players are investing in product development and AI integration to enhance diagnostic capabilities.

10/21/2026, 4:54 AM • GlobeNewswire

Vietnam Veterinary Vaccine Import Market and Top 10 Importers Guide 2023-2026 | Import Reliance and Aquaculture Growth Create Market Entry Opportunities

Vietnam's veterinary vaccine import market is expanding due to growing livestock and aquaculture sectors, with imports valued at US$172 million in 2024. The market remains highly dependent on imported vaccines, particularly from the US (34.6%), China (12.8%), and Netherlands (8.7%). International companies like Zoetis, MSD Animal Health, and Boehringer Ingelheim maintain strong positions, while foreign investment opportunities are emerging through joint ventures and local manufacturing partnerships.

10/02/2026, 4:58 AM • GlobeNewswire

Veterinary Diagnostics Market Size to Soar to USD 30.78 Billion by 2035 at a CAGR of 10.1% - SNS Insider

The global veterinary diagnostics market is projected to grow from USD 11.76 billion in 2025 to USD 30.78 billion by 2035, driven by increasing pet ownership, zoonotic disease surveillance, and advancements in point-of-care testing and molecular diagnostics. North America leads with 39% market share, while Asia-Pacific shows the fastest growth. Reagents & kits dominate products, while companion animals represent 61% of the market.

09/28/2026, 10:00 AM • GlobeNewswire

Veterinary Diagnostic Markets Report Now Available — See Exactly How IDEXX, Zoetis, Antech, Roche, and Thermo Fisher Are Positioned to Win Through 2030

A comprehensive 249-page veterinary diagnostics market report covering 15 countries and 32 companies has been released, forecasting market trends through 2030. The report analyzes growth drivers including pet ownership patterns, agricultural modernization, and the One Health movement, while examining competitive positioning of major players like IDEXX, Zoetis, Antech, Roche, and Thermo Fisher across various diagnostic assay types, animal categories, and applications.

09/07/2026, 6:38 AM • GlobeNewswire

Global Veterinary Medical Devices Market to Reach $9.1 Billion by 2030, Driven by Rising Pet Ownership and Technological Innovation in Animal Healthcare

The global veterinary medical devices market is projected to grow from $6.5 billion in 2024 to $9.1 billion by 2030 at a 6.1% CAGR, driven by pet humanization trends, expanding pet insurance coverage, and AI-enabled diagnostic innovations. North America dominates with 55.9% market share, while emerging markets present long-term growth opportunities.

08/25/2026, 2:53 PM • GlobeNewswire

DEADLINE ALERT for AVAV, CALX, ZTS, and LCID: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Class action lawsuits have been filed against AeroVironment, Calix, Zoetis, and Lucid Group, alleging that company executives made materially false statements and failed to disclose material adverse facts about their businesses. The lawsuits cover various issues including understated competition, supply chain problems, declining product adoption, and manufacturing disruptions. Lead plaintiff deadlines range from July 27-28, 2026.

07/27/2026, 10:49 AM • GlobeNewswire

ZOETIS DEADLINE: ROSEN, HIGHLY RECOGNIZED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Secure Counsel Before Important July 27 Deadline in Securities Class Action – ZTS

A securities class action lawsuit has been filed against Zoetis Inc. for allegedly making false and misleading statements about its Companion Animal products during January 2025 to May 2026. The lawsuit claims the company failed to disclose weakening veterinarian adoption of its Librela pain treatment following FDA safety warnings, significant market share losses in Simparica Trio to competitors, and declining sales in dermatology products Apoquel and Cytopoint. Investors who purchased securities during this period may be eligible for compensation.

07/22/2026, 11:10 PM • GlobeNewswire

ZOETIS CLASS ACTION DEADLINE MONDAY JULY 27th: Bragar Eagel & Squire, P.C. Reminds Zoetis, Inc. Investors to Contact the Firm Before the July 27th Lead Plaintiff Deadline

A class action lawsuit has been filed against Zoetis, Inc. for allegedly making materially false statements and failing to disclose material adverse facts during the period from January 14, 2025 to May 6, 2026. The complaint alleges that Zoetis concealed weakening veterinarian adoption of its Librela product due to FDA safety warnings, significant market share losses in Simparica Trio to competitors, and declining market share for dermatology products Apoquel and Cytopoint. Investors have until July 27, 2026 to apply to be appointed as lead plaintiff.

07/20/2026, 5:50 PM • GlobeNewswire

Deadline Alert: Zoetis Inc. (ZTS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

A securities fraud class action lawsuit has been filed against Zoetis Inc. for allegedly making materially false statements and failing to disclose material adverse facts about its business. The lawsuit covers investors who purchased Zoetis securities between January 14, 2025 and May 6, 2026. The company's stock declined significantly following three earnings announcements that revealed weakened demand in its Companion Animal portfolio, increased competition, and declining sales of key products including Librela, Simparica Trio, Apoquel, and Cytopoint. The deadline to file a lead plaintiff motion is July 27, 2026.

07/20/2026, 1:53 PM • GlobeNewswire

ZOETIS DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZTS

A securities class action lawsuit has been filed against Zoetis Inc. for allegedly making false and misleading statements about its Companion Animal products during the period from January 14, 2025 to May 6, 2026. The lawsuit claims the company failed to disclose weakening veterinarian adoption of its Librela pain treatment following FDA safety warnings, significant market share losses in Simparica Trio to competitors, and declining market share in dermatology products Apoquel and Cytopoint. Investors who purchased Zoetis securities during this period may be eligible for compensation. The lead plaintiff deadline is July 27, 2026.

07/19/2026, 7:47 PM • GlobeNewswire

Zoetis Inc. (ZTS) Investors: July 27, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP

A securities fraud class action lawsuit has been filed against Zoetis Inc. for allegedly making materially false statements about product adoption during the class period of January 14, 2025 through May 6, 2026. The lawsuit alleges the company misrepresented the performance of key products including Librela, Simparica Trio, Apoquel, and Cytopoint. Zoetis's stock fell 21.5% on May 7, 2026, following disappointing first quarter results showing significant decline in its Companion Animal business. Investors have until July 27, 2026, to file for lead plaintiff status.

07/18/2026, 9:40 AM • GlobeNewswire